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Objective: To examine the impact of subject characteristics on efficacy as measured by the Pearl Index (PI) in clinical trials and to make
study populations similar by matching.
Methods: Our analysis used US data from four large Phase III studies. We compared results from one fertility control patch study with
pooled data from three studies with virtually identical design on oral hormonal contraceptives. First, we identified three characteristics that
had the most impact on the PI. Second, we used these three variables and matched subjects from the patch study with those from the oral
contraceptive (OC) studies. Finally, we calculated the PIs for matched and unmatched subjects from both the patch study and the OC studies.
Results: A total of 3706 subjects were included in our analysis. The variables ‘Hispanic ethnicity’, ‘previous pregnancy’ and ‘previous use of
hormonal contraceptives’ had the most impact on the PI. The PIs for the matched patch cohort and the matched OC cohort were 2.97 and
2.48, respectively. Those for the unmatched patch cohort and the unmatched OC cohort were 10.17 and 0.90, respectively.
Conclusion: Subject characteristics strongly influence the PI in clinical studies of hormonal contraceptives. In particular, Hispanic ethnicity,
previous pregnancies and no previous use of hormonal contraceptives result in a higher PI.
Implications: PIs from different clinical trials cannot be meaningfully compared unless subject characteristics that have most impact on the
PI are similar or are made to be similar statistically as we did here by matching.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/3.0/).Keywords: Pearl Index; Contraception; Study population; Subject characteristics; Contraceptive failure1. Introduction
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0010-7824/© 2014 The Authors. Published by Elsevier Inc. This is an open acc
licenses/by-nc-nd/3.0/).ities all over the world — including the US Food and Drug
Administration and the European Medicines Agency —
stipulate assessment of efficacy by the Pearl Index (PI). The
PI is the primary endpoint of those Phase III clinical trials.
Recently approved oral contraceptives (OCs) in theUS featured
PIs between 2 and 3 (LoSeasonique: 2.74 [2]; Lo Loestrin Fe:
2.92 [3]; Quartette: 3.19 [4]) while those developed previously
showed PIs below 2 (Yasmin: 0.406 [5]; Yaz™: 1.29 [6]).
Apparently, PIs appear to be increasing over time [7].
In a PI study in the US starting in 2009, a fertility control
patch showed an unadjusted PI of 3.56 [upper 95%
confidence interval (CI) 4.95] [8] in women aged 18–45
years with no body mass index (BMI) restrictions. We
sought to explore whether this high PI could be explained byess article under the CC BY-NC-ND license (http://creativecommons.org/
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comparison with pooled data from three other hormonal
contraceptive studies (Natazia/Qlaira™, Yaz™ and
Flexyess™) starting between 2000 and 2007. First, we ran
an exploratory analysis using all available variables related
to demography, medical history and gynecological and
reproductive history. Based on the evaluation of a total of 13
variables, we identified three variables that impacted PI the
most. Second, we used these three variables and matched
subjects from the patch study with those from the pooled OC
studies by using the propensity score analysis method.
Finally, we calculated the PIs for the matched and
unmatched populations from both the patch study and the
pooled OC studies.2. Materials and methods
2.1. Studies included in the analysis
Four large Phase III studies sponsored by Bayer were
included in this analysis. The primary efficacy outcome was
contraceptive efficacy measured by the PI. Two studies were
performed only in the US [8,9]; two also had centers in
Europe. All lasted at least 1 year and included a total of 6602
women, of these 3706 women were treated in the US.
The most recent study investigated a fertility control patch
(patch) [8] while the previous studies investigated three
different oral hormonal contraceptives (OC) [6,9,10]. The
estrogen component was either ethinylestradiol (EE) or
estradiol valerate (E2V). The progestin component was
gestodene (GSD), drospirenone (DRSP) or dienogest (DNG)
in different regimens (Table 1).
2.2. Variables
The complete set of 13 variables recorded as baseline
characteristics in all four studies was included in the
analysis: age, race, Hispanic ethnicity (Y/N), BMI, alcohol
consumption (Y/N), smoking (Y/N), previous pregnancies
(Y/N), number of previous births, number of previous
abortions, history of births (Y/N), history of abortions (Y/N),
ever pregnant (Y/N) and previous use of hormonal
contraceptives (Y/N).Table 1
Studies included in the analysis
Author Contraceptive preparation
Merz 2012 Patch: 0.55 mg EE/2.1 mg GSD/patch,
3×7 days, 7 days off, APLEEK™
Bachmann 2004 Pill: 20 μg EE/3 mg DRSP; 24 days,
4 days off, YAZ™
Nelson 2013 Pill: E2V/DNG; 5-phasic regimen,
no break, QLAIRA/NATZIA™
Jensen 2012 Pill: 20 μg EE/3 mg DRSP;
flexible regimen for 24–120 days,
4 days off in case of bleeding, Flexyess™2.3. Statistics
Following the intention-to-treat principle [11], all subjects
from the US centers in the respective full analysis sets of the
studies were retained for this analysis, provided that the
demographic baseline characteristics had been recorded for
all variables included in the propensity score model.
The propensity of each woman to be included in the patch
study rather than in an OC study was calculated using several
logistic regression models. For each subject from the patch
study, one subject from OC study population was sought
who had a matching propensity score. PIs were calculated
separately for the matched and the unmatched subjects for
the patch study and for the other OC studies.
All analyses were exploratory ex post analyses. Descrip-
tive statistics of the data set were performed with version 9.2
of SAS software [12]. The propensity scores were calculated
using version 2.13.1 of R software [13], the R-function
“pscore” of the R-Package “non-random” [14], and the
propensity score matching was performed using the R-
function “ps.match” of the R-Package “non-random” using a
caliper size of 0.01. The CIs for the PIs were calculated using
the Poisson model according to Gerlinger et al. [15] and were
calculated based on all pregnancies regardless of possible
user intake errors.3. Results
A total of 6602 subjects were included in all four
studies worldwide (Table 1). A subset of 3706 subjects
were from the US and used for this analysis. Of these, 1453
subjects were recruited from the patch study and 2253
subjects were recruited from the pool of subjects from the
OC studies (Table 2).
We identified three out of 13 variables as relevant
matching criteria: (1) Hispanic ethnicity (Y/N), (2) previous
pregnancies (Y/N) and (3) previous use of hormonal
contraceptives (Y/N). By applying these three matching
criteria, 1386 subjects could be matched for one of the eight
possible combinations. Sixty-seven subjects from the patch
study and 867 from the OC studies could not be matched. In
the matched population, 254 subjects (18.3%) were of
Hispanic ethnicity, 683 subjects (49.3%) were previouslyCountry Women started, n Reference
USA 1454 [8]
Austria, Argentina,
Brazil, Poland, USA
1018 [6]
USA, Canada, Europe 2266 [10]
USA 1864 [9]
Table 2
Demographics by study type and matching status
Patch study
before matching
OC studies
before matching
Patch not
matched
Patch
matched
OC
matched
OC not
matched
Number of women 1453 2253 67 1386 1386 867
Age (mean±S.D.) 27.9±6.4 25.6±5.1 29.5±7.2 27.9±6.4 25.5±4.9 25.6±5.4
BMI (mean±S.D.) 26.8±6.2 24.0±3.9 28.0±6.6 26.8±6.1 24.0±3.9 24.2±3.9
Race
Caucasian 852 (58.6%) 1654 (73.4%) 13 (19.4%) 839 (60.5%) 918 (66.2%) 736 (84.9%)
Black 225 (15.5%) 187 (8.3%) 6 (9.0%) 219 (15.8%) 145 (10.5%) 42 (4.8%)
Hispanic 301 (20.7%) 314 (13.9%) 47 (70.1%) 254 (18.3%) 254 (18.3%) 60 (6.9%)
Asian 38 (2.6%) 55 (2.4%) 0 38 (2.7%) 37 (2.7%) 18 (2.1%)
Other 37 (2.5%) 43 (1.9%) 1 (1.5%) 36 (2.6%) 32 (2.3%) 11 (1.3%)
Ever pregnant 743 (51.1%) 885 (39.3%) 60 (89.6%) 683 (49.3%) 683 (49.3%) 202 (23.3%)
Hormonal contraceptives before study 600 (41.3%) 1286 (57.1%) 0 600 (43.3%) 600 (43.3%) 686 (79.1%)
Boldface, criteria for matching.
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ceptives prior to study start for each of the patch and the OC
users group. In the unmatched patch cohort, 70.1% of
subjects were of Hispanic ethnicity and 89.6% were
previously pregnant compared to 6.9% and 23.3% in the
unmatched OC group. In the unmatched OC cohort, 686
subjects (79.1%) used hormonal contraceptives before the
study in contrast to 0% in the unmatched patch cohort
(Table 2). Thus, Hispanic women and subjects who have
been previously pregnant were more likely to be included in
the patch study while subjects who previously used
hormonal contraceptives were more likely included in an
OC study.
The PIs of the studies before matching were 3.26 (CI
2.23–4.6) for the patch study and 1.85 (CI 1.62–2.62) for the
OC studies. The PIs for the matched patch cohort and the
matched OC cohort were 2.97 (CI 1.97–4.29) and 2.48 (CI
1.60–3.66), respectively. Those for the unmatched patch
cohort and the unmatched OC cohort were 10.17 (CI 2.77–
26.05) and 0.90 (CI 0.33–1.96), respectively (Table 3).4. Discussion
PIs appear to be increasing over time [7] as also reflected
in the high PI for the fertility control patch investigated here.
While Trussell and Portman proposed two main factors for
increasing PIs, first, the more frequent pregnancy testingTable 3
Pearl Indices
Patch study
before matching
Relevant exposure during complete study (women-years) 982.6
Pregnanciesa, n (%) 32 (2.2)
Pearl Index 3.26
95% CI for PI 2.23–4.60
a During treatment and until 7 days after last patch wear or pill intake.with more sensitive tests, and, second, the decrease in
adherence due to changes in study populations over time [7],
we focused specifically on the latter point. We felt it was
worthwhile to identify factors that might explain the rise
in PIs.
We identified three relevant subject variables as important
factors impacting the PI: (1) Hispanic ethnicity, (2) previous
pregnancies and (3) previous use of hormonal contracep-
tives. After matching the fertility control patch population
with the pooled OC population for these three subject
variables, the PIs for the two matched cohorts were equal.
We would suggest that this is strong evidence that the PI of
3.56 in the patch study is higher because of the character-
istics of the specific study population; specifically, a high
percentage of Hispanic subjects, women that gave birth or
had an abortion before and women who rarely used effective
hormonal contraception before resulted in a higher contra-
ceptive failure rate.
There is some evidence in the literature about the impact
of the study population on the PI. For example, a recent study
comparing an experimental patch to a standard pill
containing 20 μg EE and 100 μg levonorgestrel also showed
PIs of approximately 5 and 4 [16] in a comparable
population as that of the patch study presented here.
The overall PI summarizes pregnancies due to method
and subject failures. While method failures occur during
‘perfect use’, subject failures occur during ‘typical use’.
‘Typical use’ reflects how effective methods are for theOC studies
before matching
Patch not
matched
Patch
matched
OC
matched
OC not
matched
1674.0 39.3 943.3 1009.4 664.6
31 (1.4) 4 (6.0) 28 (2.0) 25 (1.8) 6 (0.7)
1.85 10.17 2.97 2.48 0.90
1.26–2.62 2.77–26.05 1.97–4.29 1.60–3.66 0.33–1.96
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or consistently [17]. Thus, subject failures are caused by non-
compliance. Westhoff et al. investigated predictors of non-
compliance including race, previous pregnancies and current
OC use. In the group of non-compliant subjects, significantly
more Hispanics and blacks as well as previously pregnant
women were found. Current OC use was numerically but not
significantly higher in the group of compliant subjects [18].
Our findings on pregnancies in these populations are well in
line. In Westhoff's logistic regression analysis, lack of
education, residential poverty, Hispanic ethnicity and obesity
continued to be associated with non-compliance. Westhoff
et al. suggest that race or ethnicity (black/Hispanic) does not
directly impact contraceptive failure rates but more likely is a
proxy for socioeconomic parameters such as low income, low
educational level, lack of insurance coverage, etc. [18].
Also, Borrero et al. described the impact of race/ethnicity
on differences in compliance. In a cohort of 6946 female
veterans, Hispanics were significantly more likely than
whites to experience gaps between refills of contraceptives.
In addition, Hispanic and black women had fewer months of
contraceptive coverage than white women [19]. In a study on
compliance comparing a contraceptive patch versus an OC,
Kaunitz et al. found higher rates of perfect compliance in
patch users independent of age, race/ethnicity and education.
In the group of OC users, all these factors influenced perfect
compliance with lower values in the group of Hispanics and
in women with lower education [20]. In addition to Hispanic
ethnicity, we found that a history of previous pregnancies
increases the likelihood of contraceptive failures. This
finding is in line with that in Dinger et al., although they
also found a positive correlation between contraceptive
failures and lower education, higher BMI and young age
(20–24 years) [21].
Interestingly, Kost et al. reported estimates of contracep-
tive failure from the 2002 National Survey of Family
Growth. They concluded that the risk of failure is strongly
affected by socioeconomic characteristics of the users, e.g.,
probability of failure higher for Hispanic and black women
than for whites, more than twice as high for women with one
or more births as for those with none, more than twice as
high for those with lower incomes than for those with higher
incomes and higher for cohabiting women than for married
women [22]. A similar pattern is seen for the incidence of
unintended pregnancies. Finer et al. found that unintended
pregnancies are highest in black or Hispanic women and in
women with low education (no high school graduation), with
low income (b100% of poverty) and with ≥2 births [23].
However, it is unclear whether unintended pregnancy is due
to no use of any kind of contraception or to imperfect use.
Finally, geography also has some influence on the PI. When
one hormonal contraceptive is investigated in American and
European population, the PIs derived from US are usually
higher than those from Europe (for example, Flexyess™:
Europe, 0.64 [24] versus USA, 1.65 [9]). This phenomenon
needs further investigation.One limitation of our analysis is that, in all four studies,
we did not specifically ask whether women wanted a child
in the future. Whether they were spacers or limiters could
well have affected compliance and eventually rates of
contraceptive failure.
Finally, the analysis presented here was conducted ex
post. A confirmation of these findings in a prospective
setting would be needed.5. Conclusion
Subject variables strongly influence the PI in clinical
studies of hormonal contraceptives. In particular, Hispanic
ethnicity, previous pregnancies and no previous use of
hormonal contraceptives result in a higher PI.
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